Genotyping. One Piece of the Puzzle to Personalize Antiplatelet Therapy

Journal of the American College of Cardiology

Volumn 56, Issue 2, 2010, Pages 112-116

  Gurbel, Paul A ^a   Tantry, Udaya S ^a   Shuldiner, Alan R ^b   Kereiakes, Dean J ^c  

^a SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c The Carl & Edyth Lindner Center for Research & Education   (United States)

Author keywords

antiplatelet therapy; CYP2C19*2; genotyping

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CALCIUM CHANNEL BLOCKING AGENT; CILOSTAZOL; CLOPIDOGREL; CYTOCHROME P450 2C18; CYTOCHROME P450 2C19; FIBRINOGEN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MULTIDRUG RESISTANCE PROTEIN 1; PRASUGREL; PROTON PUMP INHIBITOR; TICAGRELOR; TICLOPIDINE; WARFARIN;

ALLELE; CLINICAL PRACTICE; DRUG ABSORPTION; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; GENOTYPE; HETEROZYGOTE; HUMAN; ISCHEMIA; LOSS OF FUNCTION MUTATION; MEDICAL SOCIETY; PERCUTANEOUS CORONARY INTERVENTION; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION;

CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; PLATELET AGGREGATION INHIBITORS; TICLOPIDINE;

EID: 77953914877     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.04.008     Document Type: Review

References (32)

1. Damani S.B., and Topol E.J. The case for routine genotyping in dual-antiplatelet therapy. J Am Coll Cardiol 56 (2010) 109-111
2. Kereiakes D.J., and Gurbel P.A. Peri-procedural platelet function and platelet inhibition in percutaneous coronary intervention. J Am Coll Cardiol Intv 1 (2008) 111-121
3. Kazui M., Nishiya Y., Ishizuka T., et al. Identification of the human cytochrome P450 enzymes involved in the two oxidative steps in the bioactivation of clopidogrel to its pharmacologically active metabolite. Drug Metab Dispos 38 (2010) 92-99
4. Gurbel P.A., Antonino M.J., and Tantry U.S. Recent developments in clopidogrel pharmacology and their relation to clinical outcomes. Expert Opin Drug Metab Toxicol 5 (2009) 989-1004
5. Human Cytochrome P450 (CYP) Allele Nomenclature Committee. CYP2C19 allele nomenclature. http://www.cypalleles.ki.se/cyp2c19.htm Accessed March 2010
6. Shuldiner A.R., O'Connell J.R., Bliden K.P., et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy. JAMA 302 (2009) 849-857
7. Gurbel PA, Tantry US, Antonino MJ, et al. The influence of cytochrome P450 2C19*2 and *17 genotype, diplotype and metabolizer status on platelet reactivity in patients on maintenance clopidogrel therapy. Paper presented at: 59th Annual Scientific Session of the American College of Cardiology; March 13-16, 2010; Atlanta, GA.
8. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360 (2009) 354-362
9. Sibbing D., Stegherr J., Latz W., et al. Cytochrome P450 2C19 loss-of-function polymorphism and stent thrombosis following percutaneous coronary intervention. Eur Heart J 30 (2009) 916-922
10. Mega J., Simon T., Anderson J.L., et al. CYP2C19 genetic variants and clinical outcomes with clopidogrel: a collaborative meta-analysis. Circulation 120 Suppl (2009) s598
11. Simon T., Verstuyft C., Mary-Krause M., et al., French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 360 (2009) 363-375
12. Sibbing D., Koch W., Gebhard D., et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 21 (2010) 512-518
13. Mega J.L., Close S.L., Wiviott S.D., et al. ABCB1 genetic variants, pharmacodynamic response, and cardiovascular outcomes following treatment with clopidogrel and prasugrel (abstr). J Am Coll Cardiol 55 Suppl A (2010) A113
14. Sibbing D., von Beckerath N., Morath T., et al. Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel. Eur Heart J (2010 Feb 16) [E-pub ahead of print]
15. Singla A., Antonino M.J., Bliden K.P., et al. The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. Am Heart J 158 (2009) e1-e784
16. Sibbing D., von Beckerath O., Schömig A., et al. Impact of body mass index on platelet aggregation after administration of a high loading dose of 600 mg of clopidogrel before percutaneous coronary intervention. Am J Cardiol 100 (2007) 203-205
17. Ang L., Palakodeti V., Khalid A., et al. Elevated plasma fibrinogen and diabetes mellitus are associated with lower inhibition of platelet reactivity with clopidogrel. J Am Coll Cardiol 52 (2008) 1052-1059
18. Bonello L., Tantry U.S., Marcucci R., et al. Consensus and future directions on the definition of high on-treatment platelet reactivity to ADP. J Am Coll Cardiol (2010) In press
19. Breet N., van Werkum J., Bouman H., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 303 (2010) 754-762
20. Bonello L., Camoin-Jau L., Arques S., et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: a multicenter randomized prospective study. J Am Coll Cardiol 51 (2008) 1404-1411
21. Campo G., Valgimigli M., Gemmati D., et al. Poor responsiveness to clopidogrel: drug-specific or class-effect mechanism?. Evidence from a clopidogrel-to-ticlopidine crossover study. J Am Coll Cardiol 50 (2007) 1132-1137
22. Lau W.C., Gurbel P.P., Watkins P.B., et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 109 (2004) 166-171
23. Jeong Y.H., Lee S.W., Choi B.R., et al. Randomized comparison of adjunctive cilostazol versus high maintenance dose clopidogrel in patients with high post-treatment platelet reactivity: results of the ACCEL-RESISTANCE (Adjunctive Cilostazol Versus High Maintenance Dose Clopidogrel in Patients With Clopidogrel Resistance) randomized study. J Am Coll Cardiol 53 (2009) 1101-1109
24. Valgimigli M., Campo G., de Cesare N., et al. Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized tailoring treatment with tirofiban in patients showing resistance to aspirin and/or resistance to clopidogrel study. Circulation 119 (2009) 3215-3222
25. Mega J., Close S.L., Wiviott S.D., et al. Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119 (2009) 2553-2560
26. Gurbel P.A., Bliden K.P., Butler K., et al. Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation 121 (2010) 1188-1199
27. Gurbel P.A., Bliden K.P., Antonino M.J., et al. The effect of elinogrel on high platelet reactivity during dual antiplatelet therapy and the relation to CYP2C19*2 genotype: first experience in patients. J Thromb Haemost 8 (2010) 43-53
28. Aleil B., Jacquemin L., DePoli F., et al. Clopidogrel 150 mg/day to overcome low responsiveness in patients undergoing elective percutaneous coronary intervention: results from the VASP-02 (Vasodilator-Stimulated Phosphoprotein-02) randomized study. J Am Coll Cardiol Intv 1 (2008) 631-638
29. Cattaneo M. New P2Y(12) inhibitors. Circulation 121 (2010) 171-179
30. Gurbel PA, Bliden KP, Ryan K, et al. Influence of CYP2C19 polymorphism on antiplatelet effects of clopidogrel and long-term recurrent ischemic event occurrence. Paper presented at: 58th Annual Scientific Session of the American College of Cardiology; March 29-31, 2009; Orlando, FL.
31. Collet J.P., Hulot J.S., Pena A., et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 373 (2009) 309-317
32. James S., Akerblom A., Cannon C.P., et al. Comparison of ticagrelor, the first reversible oral P2Y(12) receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the Platelet Inhibition and Patient Outcomes (PLATO) trial. Am Heart J 157 (2009) 599-605